Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 27.85%. A quarter ago, it was expected that this company would post a loss of $0.72 per share when it actually produced a loss of $0.34, delivering a surprise of 52.78%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Foghorn Therapeutics Inc., which belongs to the Zacks Medical - Drugs industry, posted revenues of $5.77 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 17.59%. This compares to year-ago revenues of $4.18 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Foghorn Therapeutics Inc. Shares have added about 5.3% since the beginning of the year versus the S&P 500's gain of 7%.

What's Next for Foghorn Therapeutics Inc.

While Foghorn Therapeutics Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Foghorn Therapeutics Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.65 on $7.45 million in revenues for the coming quarter and -$2.05 on $37.45 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Avalo Therapeutics, Inc. (AVTX), another stock in the same industry, has yet to report results for the quarter ended December 2023.

This company is expected to post quarterly loss of $4.76 per share in its upcoming report, which represents a year-over-year change of +98.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Avalo Therapeutics, Inc.'s revenues are expected to be $0.3 million, down 66.7% from the year-ago quarter.

4 Oil Stocks with Massive Upsides

Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold." 

Zacks Investment Research has just released an urgent special report to help you bank on this trend. 

In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations. 

Download your free report now to see them.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Foghorn Therapeutics Inc. (FHTX) : Free Stock Analysis Report

Avalo Therapeutics, Inc. (AVTX) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.